Literature DB >> 3688011

Effect of fenofibrate treatment on type III hyperlipoproteinemia.

J C Fruchart1, J Davignon, J M Bard, A M Grothe, A Richard, C Fievet.   

Abstract

The effect of treatment with fenofibrate was investigated in nine patients (seven men) presenting with type III hyperlipoproteinemia. This therapy produced a statistically significant decrease in serum triglyceride, cholesterol, apolipoproteins B, CII, CIII, and E levels. Particular attention was focused on lipoproteins containing apolipoprotein B. The concentration of particles recognized by monoclonal antibodies (BL3, BL5, and BL7), associated with atherosclerotic disease, was lowered by the treatment. The most dramatic decrease was observed for lipoproteins LpE:B and LpCIII:B, which are particularly enhanced in type III hyperlipoproteinemia.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3688011     DOI： 10.1016/0002-9343(87)90874-6

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


  7 in total

1.  Severe xanthomatosis associated with familial apolipoprotein E deficiency.

Authors:  G Feussner
Journal:  J Clin Pathol       Date:  1996-12       Impact factor: 3.411

2.  Peroxisome proliferator-activated receptor-α activation promotes macrophage reverse cholesterol transport through a liver X receptor-dependent pathway.

Authors:  Kazuhiro Nakaya; Junichiro Tohyama; Snehal U Naik; Hiroyuki Tanigawa; Colin MacPhee; Jeffrey T Billheimer; Daniel J Rader
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-03-24       Impact factor: 8.311

Review 3.  Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia.

Authors:  J A Balfour; D McTavish; R C Heel
Journal:  Drugs       Date:  1990-08       Impact factor: 9.546

4.  The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia.

Authors:  G Feussner; M Eichinger; R Ziegler
Journal:  Clin Investig       Date:  1992-11

5.  Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia.

Authors:  M van Dam; M Zwart; F de Beer; A H M Smelt; M H Prins; M D Trip; L M Havekes; P J Lansberg; J J P Kastelein
Journal:  Heart       Date:  2002-09       Impact factor: 5.994

6.  Clinical features of type III hyperlipoproteinemia: analysis of 64 patients.

Authors:  G Feussner; A Wagner; B Kohl; R Ziegler
Journal:  Clin Investig       Date:  1993-05

Review 7.  Selective peroxisome proliferator-activated receptor α modulators (SPPARMα): the next generation of peroxisome proliferator-activated receptor α-agonists.

Authors:  Jean-Charles Fruchart
Journal:  Cardiovasc Diabetol       Date:  2013-05-31       Impact factor: 9.951
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.